Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAR4 program
- Development stage
- Preclinical
- Lead developer
- Vanderbilt University
- Modality
- Small Molecules
01
Overview
The PAR4 program at the Warren Center for Neuroscience Drug Discovery (WCNDD) is focused on developing small molecule modulators of Protease-Activated Receptor 4 (PAR4). PAR4 is a G protein-coupled receptor that plays a significant role in inflammatory signaling and platelet activation. The program is currently exploring the therapeutic potential of PAR4 modulation for treating neuroinflammation and chronic kidney disease (CKD). As of the latest reports, the program is in the hit-to-lead and lead optimization stages of preclinical development.
- Other names
- PAR4 small moleculePAR-4 small moleculePAR 4 small molecule
02
Targets
PAR4 (Protease-activated receptor 4)
Beyond the preview
Go deeper on PAR4 program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAR4 program.